Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
emtricitabine/tenofovir alafenamide (Descovy®)
Reference No. 2771
Publication date:
05/10/2016
Appraisal information
emtricitabine/tenofovir alafenamide (Descovy®) 200 mg/10 mg film-coated tablet
emtricitabine/tenofovir alafenamide (Descovy®) 200 mg/25 mg film-coated tablet
Company:
Gilead Sciences Ltd
BNF category:
Infections
NMG meeting date:
20/07/2016
AWMSG meeting date:
21/09/2016
Submission Type:
Limited Submission
Status:
Recommended
Advice No:
2716
Ratification by Welsh Government:
04/10/2016
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Emtricitabine/tenofovir alafenamide (Descovy®) is recommended as an option for use within NHS Wales in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV 1).
Final Appraisal Recommendation (FAR)
Download
Emtricitabine_tenofovir alafenamide (Descovy) 2771 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
Emtricitabine_tenofovir alafenamide (Descovy) 2771 ASAR
Clinical Expert (CE) Summary
Download
Emtricitabine_ tenofovir alafenamide (Descovy) 2771 CE summary